ISRCTN24855462 https://doi.org/10.1186/ISRCTN24855462

A phase II randomised feasibility study of chemoresection or surgical management in low risk non muscle invasive bladder cancer

Submission date 14/01/2015	**Recruitment status** No longer recruiting	[X] Prospectively registered [X] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 15/01/2015	**Overall study status** Completed	
Last Edited 18/08/2022	**Condition category** Cancer	

Plain English summary of protocol
http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-chemotherapy-and-surgery-for-early-bladder-cancer-caliber

Study website
http://www.icr.ac.uk/our-research/our-research-centres/clinical-trials-and-statistics-unit/clinical-trials/caliber

Contact information

Type(s)
Scientific

Contact name
Mr Steven Penegar

Contact details
Clinical Trials & Statistics Unit at the Institute of Cancer Research (ICR-CTSU)
The Institute of Cancer Research
London
United Kingdom
SM2 5NG

Additional identifiers

EudraCT/CTIS number
2013-005095-18

IRAS number

ClinicalTrials.gov number
NCT02070120

Secondary identifying numbers
17640

Study information

Scientific Title
A phase II randomised feasibility study of chemoresection or surgical management in low risk non muscle invasive bladder cancer

Acronym
CALIBER

Study objectives
Current hypothesis as of 10/04/2017:
To demonstrate that chemoresection has sufficient activity against NMIBC to warrant further investigation of its role as a potential alternative to surgical intervention for low risk NMIBC recurrence.

Previous hypothesis:
CALIBER aims to demonstrate that chemoresection will enable 60% of participants to avoid surgical intervention for low risk NMIBC recurrence, as assessed by response rate at 3 months.

Ethics approval required
Old ethics approval format

Ethics approval(s)
NRES Committee South Central - Hampshire B, 29/08/2014, ref: 14/SC/1223

Study design
Randomised; Interventional

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied
Topic: Cancer; Subtopic: Bladder Cancer; Disease: Bladder (superficial)

Interventions
Chemoresection group: 4 once weekly instillations of 40mg MMC as outpatients
Surgical management group: Surgery according to local practice

Intervention Type
Drug

Phase
Phase II

Drug/device/biological/vaccine name(s)
Mitomycin C

Primary outcome measure
Complete response to chemoresection 3 months post-treatment

Secondary outcome measures
Added 12/10/2016:

In the chemoresection group:
1. Treatment compliance

In both groups:
2. Time to recurrence in patients disease free at 3 months
3. Transurethral resection and biopsy rates
4. Progression-free survival
5. Toxicity
6. Quality of life
7. Health service utilisation

Overall study start date
01/11/2014

Completion date
30/09/2019

Eligibility

Key inclusion criteria
Current inclusion criteria as of 29/03/2017:
1. Written informed consent
2. NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables).
3. Histologically confirmed TCC at original diagnosis
4. Aged 16 or over

5. Satisfactory pre-treatment haematology values haemoglobin > 100 g/L and serum creatinine < 1.5xULN
6. Negative pregnancy test for women of child-bearing potential

Previous inclusion criteria from 12/10/2016 to 29/03/2017:
1. Written informed consent
2. NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤5 using EORTC risk tables).
3. Histologically confirmed TCC at original diagnosis
4. Aged 16 or over
5. Satisfactory pre-treatment haematology values haemoglobin > 100 g/L and serum creatinine < 1.5xULN
6. Negative pregnancy test for women of child-bearing potential

Original inclusion criteria:
1. Written informed consent
2. NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 NMIBC with a risk of recurrence score of <=5 using EORTC risk tables)
3. Histologically confirmed TCC at original and any subsequent diagnoses
4. Aged 16 or over
5. Satisfactory pre-treatment haematology values Hb > 100 g/L and serum creatinine < 1.5xULN
6. Negative pregnancy test for women of child-bearing potential

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
Planned Sample Size: 174; UK Sample Size: 174

Total final enrolment
82

Key exclusion criteria
Current exclusion criteria as of 29/03/2017:
1. Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
2. Any history of histologically confirmed non-TCC bladder cancer
3. Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
4. Any prior treatment of the trial entry recurrence (including biopsy)
5. Previous MMC chemotherapy other than a single instillation at diagnostic surgery
6. Known allergy to MMC
7. Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
8. Known or suspected reduced bladder capacity (<100ml)

9. Significant bleeding disorder
10. Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
11. Active or intractable urinary tract infection
12. Urethral stricture or anything impeding the insertion of a catheter
13. Large narrow neck diverticula
14. Significant urinary incontinence
15. Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
16. Unable or unwilling to comply with study procedures or follow up schedule

Previous exclusion criteria from 12/10/2016 to 29/03/2017:
1. Any history of: grade 3/high grade or T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
2. Any history of histologically confirmed non-TCC bladder cancer
3. Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
4. Previous MMC chemotherapy other than a single instillation at diagnostic surgery
5. Known allergy to MMC
6. Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
7. Known or suspected reduced bladder capacity (<100ml)
8. Significant bleeding disorder
9. Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active
10. Active or intractable urinary tract infection
11. Urethral stricture or anything impeding the insertion of a catheter
12. Large narrow neck diverticula
13. Significant urinary incontinence
14. Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
15. Unable or unwilling to comply with study procedures or follow up schedule

Original exclusion criteria:
1. Risk of recurrence score >5 at original or any subsequent diagnoses (including any history of: grade 3 or T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year)
2. Previous MMC chemotherapy other than a single instillation at diagnostic surgery
3. Known allergy to MMC
4. Carcinoma involving the prostatic urethra or upper urinary tract (participants should have received an ultrasound of the upper urinary tract within 2 years prior to randomisation)
5. Known or suspected reduced bladder capacity (<100ml)
6. Significant bleeding disorder
7. Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active
8. Any other malignancy in the past 2 years (except: non-melanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix, DCIS/LCIS of the breast or prostate cancer in patients who have a life expectancy of >5 years upon trial entry)
9. Active or intractable urinary tract infection

10. Urethral stricture or anything impeding the insertion of a catheter
11. Large narrow neck diverticula
12. Significant urinary incontinence
13. Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
14. Unable or unwilling to comply with study procedures or follow up schedule

Date of first enrolment
28/01/2015

Date of final enrolment
04/09/2017

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Medway Maritime Hospital
Windmill Road
Gillingham
United Kingdom
ME7 5NY

Study participating centre
Royal Bournemouth Hospital
Castle Lane East
Bournemouth
United Kingdom
BH7 7DW

Study participating centre
Cumberland Infirmary
Newtown Road
Carlisle
United Kingdom
CA2 7HY

Study participating centre

West Cumberland Hospital
Homewood Rd
Whitehaven
United Kingdom
CA28 8JG

Study participating centre
Wythenshawe Hospital
Southmoor Road
Wythenshawe
United Kingdom
M23 9LT

Study participating centre
Withington Community Hospital
Nell Lane
Manchester
United Kingdom
M20 2LR

Study participating centre
Royal Devon and Exeter Hospital
Barrack Road
Exeter
United Kingdom
EX2 5DW

Study participating centre
Royal Surrey County Hospital
Egerton Road
Guildford
United Kingdom
GU2 7XX

Study participating centre
Basingstoke & North Hampshire Hospital
Aldermaston Road
Basingstoke
United Kingdom
RG24 9NA

Study participating centre
St James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF

Study participating centre
Croydon University Hospital
London Road
Thornton Heath
United Kingdom
CR7 7YE

Study participating centre
Freeman Hospital
Freeman Road
Newcastle upon Tyne
United Kingdom
NE7 7DN

Study participating centre
Royal Oldham Hospital
Rochdale Road
Manchester
United Kingdom
OL1 2JH

Study participating centre
Basingstoke & North Hampshire Hospital
Aldermaston Road
Basingstoke
United Kingdom
RG24 9NA

Study participating centre
Ipswich Hospital
Heath Road
Ipswich

United Kingdom
IP4 5PD

Study participating centre
Leicester General Hospital
Gwendolen Road
Leicester
United Kingdom
LE5 4PW

Study participating centre
New Cross Hospital
Wednesfield Road
Wolverhampton
United Kingdom
WV10 0QP

Study participating centre
Darent Valley Hospital
Darenth Wood Road
Dartford
United Kingdom
DA2 8DA

Study participating centre
Broomfield Hospital
Court Road
Chelmsford
United Kingdom
CM1 7ET

Study participating centre
James Cook University Hospital
Marton Road
Middlesbrough
United Kingdom
TS4 3BW

Study participating centre

Hereford County Hospital
Union Walk
Hereford
United Kingdom
HR1 2ER

Study participating centre
University College Hospital
250 Euston Road
London
United Kingdom
NW1 2PG

Study participating centre
Pinderfields Hospital
Aberford Road
Wakefield
United Kingdom
WF1 4DG

Study participating centre
Macclesfield District General Hospital
Victoria Road
Macclesfield
United Kingdom
SK10 3BL

Study participating centre
Dorset County Hospital
Williams Avenue
Dorchester
United Kingdom
DT1 2JY

Study participating centre
St Richard's Hospital
Spitalfield Lane
Chichester
United Kingdom
PO19 6SE

Study participating centre
Worthing Hospital
Lyndhurst Road
Worthing
United Kingdom
BN11 2DH

Study participating centre
Worcestershire Royal Hospital
Charles Hastings Way
Worcester
United Kingdom
WR5 1DD

Study participating centre
Royal Hallamshire Hospital
Glossop Road
Sheffield
United Kingdom
S10 2JF

Study participating centre
Royal Preston Hospital
Sharoe Green Lane North
Preston
United Kingdom
PR2 9HT

Study participating centre
Cheltenham General Hospital
Sandford Road
Cheltenham
United Kingdom
GL53 7AN

Study participating centre
Southampton General Hospital
Tremona Road
Southampton

United Kingdom
SO16 6YD

Study participating centre
Derriford Hospital
Derriford Road
Plymouth
United Kingdom
PL6 8DH

Study participating centre
Northwick Park Hospital
Watford Road
Harrow
United Kingdom
HA1 3UJ

Study participating centre
Princess Alexandra Hospital
Hamstel Road
Harlow
United Kingdom
CM20 1QX

Sponsor information

Organisation
The Institute of Cancer Research

Sponsor details
-
London
England
United Kingdom
SW7 3RP

Sponsor type
University/education

Website
http://www.icr.ac.uk/

ROR
https://ror.org/043jzw605

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
The main trial results will be published in a peer-reviewed journal, on behalf of all collaborators. Publication of primary outcome is planned for 2018.

Intention to publish date
31/12/2019

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are/will be available upon request from caliber-icrctsu@icr.ac.uk.

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other publications	recruitment aids	01/11/2016		Yes	No
Other publications	recruitment aids	01/05/2017		Yes	No

Results article	results	01/03/2018		Yes	No
Results article	results	01/04/2018		Yes	No
Results article	12-month results	01/03/2019		Yes	No
Results article	results	01/06/2020		Yes	No
Protocol file	version 6	20/06/2017	18/08/2022	No	No
HRA research summary			28/06/2023	No	No